<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00244725</url>
  </required_header>
  <id_info>
    <org_study_id>ITI101711</org_study_id>
    <nct_id>NCT00244725</nct_id>
  </id_info>
  <brief_title>Odiparcil For The Prevention Of Venous Thromboembolism</brief_title>
  <official_title>A Dose Ranging Trial for the Evaluation of the Safety, Tolerability and Efficacy of Odiparcil in the Prevention of Venous Thromboembolism Following Total Knee Replacement Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Odiparcil is being studied to determine if it can prevent blood clots from forming after a
      total knee replacement and also to prove that odiparcil is safe.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">September 2006</completion_date>
  <primary_completion_date type="Actual">September 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Total VTE Event Over 10 ± 2 Days of Treatment</measure>
    <time_frame>Up to Visit 7 (10 ± 2 days of treatment)</time_frame>
    <description>Participants were assessed for VTE at all study visits and at the end of study (Day 10±2) or at early withdrawal. Any participant who remained asymptomatic for VTE at the end of the study did not receive a mandatory bilateral venogram following at least 8 days on study medication. Participants who were withdrawn early and had been objectively confirmed to have a VTE event by a method other than venography were not required to undergo venography. A participant was included in the Independent Central Adjudication Committee (ICAC)-adjudicated incidence of total VTE if he/ she experienced any of adjudicated asymptomatic deep vein thrombosis (DVT) at early withdrawal or after 8-12 days of study treatment and no later than 1 day after end of study treatment, adjudicated symptomatic DVT or pulmonary embolism (PE) at any time during study treatment or death adjudicated to be related to VTE during study treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Proximal DVT Over 10 ± 2 Days of Treatment</measure>
    <time_frame>Up to 12 days</time_frame>
    <description>Proximal DVT is defined as DVT in or above the popliteal vein. A participant was considered to have had an asymptomatic evaluable venogram if the ICAC answer to the DVT question was 'Yes' or 'No', and to have had an adjudicated asymptomatic DVT if the answer was 'Yes'. A participant who reported symptoms of DVT was considered to had an adjudicated objectively confirmed symptomatic DVT if the ICAC answer to the question 'Was a symptomatic DVT identified?' was 'Yes' and the event happened no more than 12 days after start of study treatment (unless exemption for extended treatment was granted by the medical monitor) and no more than 1 day after end of study treatment. In both asymptomatic and symptomatic DVT, the participant was considered to had a proximal DVT if either of the ICAC answers to the questions 'Left proximal' and 'Right proximal' was 'DVT'. Percentage of participants with proximal DVT over 10 ± 2 days of treatment were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Distal DVT Over 10 ± 2 Days of Treatment</measure>
    <time_frame>Up to 12 days</time_frame>
    <description>A participant was considered to have had an asymptomatic evaluable venogram if the ICAC answer to the DVT question was 'Yes' or 'No', and to have had an adjudicated asymptomatic DVT if the answer was 'Yes'. A participant who reported symptoms of DVT was considered to had an adjudicated objectively confirmed symptomatic DVT if the ICAC answer to the question 'Was a symptomatic DVT identified?' was 'Yes' and the event happened no more than 12 days after start of study treatment (unless exemption for extended treatment was granted by the medical monitor) and no more than 1 day after end of study treatment. In both asymptomatic and symptomatic DVT, the participant was considered to had a distal DVT if either of the investigator's answers to the questions 'Left distal' and 'Right distal' is 'DVT'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With PE Over 10 ± 2 Days of Treatment</measure>
    <time_frame>Up to 12 days</time_frame>
    <description>Participant who reported symptoms of PE were considered to have had an adjudicated objectively confirmed symptomatic PE if the ICAC answer to the question 'Was a PE identified?' was 'Yes'. E was characterized as fatal PE non-fatal PE and total PE events. Data has been presented for fatal PE non-fatal PE and total PE events over 12 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Death Due to VTE Over 10 ± 2 Days of Treatment</measure>
    <time_frame>Up to 12 days</time_frame>
    <description>A participant was considered dead from an adjudicated VTE-related cause if the death classification was recorded as 'Fatal PE'. A participant was considered to have died from an investigator-assessed VTE-related cause if the investigator's death classification was recorded as 'Fatal PE'. Number of death due to VTE over 10 ± 2 days of treatment were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Total Asymptomatic VTE Over 10 ± 2 Days of Treatment</measure>
    <time_frame>Up to 12 days</time_frame>
    <description>A participant was included in the Independent Central Adjudication Committee (ICAC)-adjudicated incidence of total VTE if experienced any of adjudicated asymptomatic deep vein thrombosis (DVT) at early withdrawal or after 8-12 days of study treatment and no later than 1 day after end of study treatment, adjudicated symptomatic DVT or PE at any time during study treatment or death adjudicated to be related to VTE during study treatment. A participant was considered to have had an asymptomatic evaluable venogram if the ICAC answer to the DVT question was 'Yes' or 'No', and to have had an adjudicated asymptomatic DVT if the answer was 'Yes'. The participant was considered to had a proximal DVT if either of the investigator's answers to the questions 'Left distal' and 'Right distal' is 'DVT'. The participant was considered to had a distal DVT if either of the investigator's answers to the questions 'Left distal' and 'Right distal' is 'DVT'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Total Symptomatic VTE Over 10 ± 2 Days of Treatment</measure>
    <time_frame>Up to 12 days</time_frame>
    <description>A participant who reported symptoms of DVT was considered to had an adjudicated objectively confirmed symptomatic DVT if the ICAC answer to the question 'Was a symptomatic DVT identified?' was 'Yes' and the event happened no more than 12 days after start of study treatment (unless exemption for extended treatment was granted by the medical monitor) and no more than 1 day after end of study treatment. The participant was considered to had a proximal DVT if either of the investigator's answers to the questions 'Left distal' and 'Right distal' was 'DVT'. The participant was considered to had a distal DVT if either of the investigator's answers to the questions 'Left distal' and 'Right distal' was 'DVT'. Percentage of participants with total symptomatic (distal and proximal) VTE over 10 ± 2 days of treatment were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of Trough Anti-IIa Activity Over the Duration of Treatment and Follow-up</measure>
    <time_frame>Up to 68 days</time_frame>
    <description>In all participants, additional 3 milliliter of blood was collected at the time of other blood sampling as follow: Baseline, Day 3 (predose, 2, 4, 8, 10, and 12 hours post dose), Day 5 (predose), and Day 10 (predose) or early withdrawal from study medication for the assessment of anti-factor IIa activity. Samples were collected in 3.8% sodium citrate tubes and immediately chilled in ice. Plasma were centrifuged and frozen at approximately -20ºC until time of shipment to the regional central laboratory. Concentration of Trough Anti-IIa Activity over the duration of treatment and follow-up were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Major Bleeds Over 10 ± 2 Days of Treatment</measure>
    <time_frame>Up to 12 days</time_frame>
    <description>A participant was included in the ICAC-adjudicated incidence of major bleeding if participant experienced an adjudicated major bleed up to 12 days after the start of study treatment and no later than 1 day after end of study treatment. Major bleed was defined as clinically overt bleeding, 1) Clinical overt bleeding: clinically apparent bleeding or signs and/or symptoms suggestive of bleeding with confirmatory imaging studies (e.g., ultrasound, computed tomography) 2. Critical Site Involvement: Intracranial, retroperitoneal, intra-ocular, intraspinal, pericardial. 3. Decrease in Hgb &gt; 2 g/dL from baseline, 4. Transfusion of &gt; 2 units of packed RBCs, 5. Medical or Surgical Intervention for the Reported Bleed, 6. Fatal Bleed. If the event satisfied one of the above criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With VTE and/or Major Bleeding Over 10±2 Days of Treatment</measure>
    <time_frame>Up to 12 days</time_frame>
    <description>A participant was included in the ICAC-adjudicated incidence of major bleeding if experienced an adjudicated major bleed up to 12 days after the start of study treatment and no later than 1 day after end of study treatment. Percentage of participants with VTE and/or major bleeding over 10±2 days of treatment were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Total VTE Any Time After Start of Treatment</measure>
    <time_frame>Up to Visit 9 (Day 28 post treatment)</time_frame>
    <description>Participants were assessed for VTE at all study visits and at the end of the study (Day 10±2) or at early withdrawal. Any participant who remained asymptomatic for VTE at the end of the study were received a mandatory bilateral venogram. Participants who were withdrawn early and had been objectively confirmed to have a VTE event by a method other than venography were not required to undergo venography. A participant was included in the ICAC-adjudicated incidence of total VTE if experienced any of adjudicated asymptomatic DVT at early withdrawal or after 8-12 days of study treatment and no later than 1 day after end of study treatment, adjudicated symptomatic DVT or PE at any time during study treatment or death adjudicated to be related to VTE during study treatment. Percentage of participants with total VTE any time after start of treatment were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Elevated Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Direct Bilirubin (DB) and Total Bilirubin (TB) by 2 Fold and 3 Fold From Upper Normal Limits (ULN) Any Time On-treatment</measure>
    <time_frame>Up to 12 days</time_frame>
    <description>The ranges (low concern value; high concern value) for AST (none; &gt; 3 fold upper normal limit (ULN) ), ALT (none; &gt;3 fold ULN), total bilirubin (none; &gt;= 34.2 micromole per litre [umol/L]), Direct bilirubin (none; &gt;= 34.2 umol/L). Percentage of participants with elevated values by 2 fold and 3 fold from ULN any time on-treatment were reported.</description>
  </secondary_outcome>
  <enrollment type="Actual">961</enrollment>
  <condition>Deep Vein Thrombosis</condition>
  <condition>Fibrillation, Atrial</condition>
  <condition>Venous Thromboembolism</condition>
  <condition>Pulmonary Embolism</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Odiparcil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Coumadin</intervention_name>
    <other_name>Odiparcil</other_name>
    <other_name>Warfarin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women must be unable to have children.

          -  Will have a total knee replacement.

        Exclusion Criteria:

          -  Allergic to any X-ray dye.

          -  Allergies or reactions to warfarin or coumadin.

          -  Previous VTE (venous thromboembolism) or deep vein thrombosis (DVT).

          -  On anticoagulation therapy.

          -  Renal impairment.

          -  Participated in any clinical trial in the past 30 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Banning</city>
        <state>California</state>
        <zip>92220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Yuba City</city>
        <state>California</state>
        <zip>95991</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80907</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lonetree</city>
        <state>Colorado</state>
        <zip>80124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Deland</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sarsota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <state>Florida</state>
        <zip>33701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21215-5271</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Warren</city>
        <state>Michigan</state>
        <zip>48089</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Altoona</city>
        <state>Pennsylvania</state>
        <zip>16601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Camp Hill</city>
        <state>Pennsylvania</state>
        <zip>17011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Huntington</city>
        <state>West Virginia</state>
        <zip>25701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Marshfield</city>
        <state>Wisconsin</state>
        <zip>54449</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Southport</city>
        <state>Queensland</state>
        <zip>4215</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Geelong</city>
        <state>Victoria</state>
        <zip>3220</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ringwood East</city>
        <state>Victoria</state>
        <zip>3135</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Windsor</city>
        <state>Victoria</state>
        <zip>3181</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90020-090</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90035-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3J 3M7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ajax</city>
        <state>Ontario</state>
        <zip>L1S 2J5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Don Mills</city>
        <state>Ontario</state>
        <zip>M3C 1W3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 2P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>North York</city>
        <state>Ontario</state>
        <zip>M3M 2G2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <zip>L1G 2B9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Scarborough</city>
        <state>Ontario</state>
        <zip>M1W 3W3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2J 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Charlottetown</city>
        <state>Prince Edward Island</state>
        <zip>C1A 1L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <zip>G1J 1Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sainte Jerome</city>
        <state>Quebec</state>
        <zip>J7Z 5T3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chennai</city>
        <zip>600 040</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Secunderabad</city>
        <zip>500 003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kfar Saba</city>
        <zip>44281</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Petach Tikva</city>
        <zip>49372</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tel-Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Riga</city>
        <zip>LV1004</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Riga</city>
        <zip>LV1005</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kaunas</city>
        <zip>LT-50009</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Klaipeda</city>
        <zip>LT-92288</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vilnius</city>
        <zip>LT-04128</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bialystok</city>
        <zip>15-276</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Krakow</city>
        <zip>31-862</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sosnowiec</city>
        <zip>41-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-043</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Irkutsk</city>
        <zip>664003</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kurgan</city>
        <zip>640014</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>117415</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mosocow</city>
        <zip>115516</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mosocow</city>
        <zip>117593</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rostov- on- Don</city>
        <zip>344718</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0084</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Centurion</city>
        <zip>157</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pretoria</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cherkasy</city>
        <zip>18009</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dnepropetrovsk</city>
        <zip>49005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kyiv</city>
        <zip>03103</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kyiv</city>
        <zip>04107</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vinnitsa</city>
        <zip>21032</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>West Midlands</state>
        <zip>B18 7QH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bournmouth</city>
        <zip>BH7 7DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fife</city>
        <zip>KY2 5AH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>SE5 9JP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wigan</city>
        <zip>WN6 9EP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>India</country>
    <country>Israel</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>Mexico</country>
  </removed_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 25, 2005</study_first_submitted>
  <study_first_submitted_qc>October 26, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2005</study_first_posted>
  <results_first_submitted>March 21, 2017</results_first_submitted>
  <results_first_submitted_qc>March 21, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 2, 2017</results_first_posted>
  <last_update_submitted>March 21, 2017</last_update_submitted>
  <last_update_submitted_qc>March 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>deep vein thrombosis</keyword>
  <keyword>total knee replacement</keyword>
  <keyword>PE</keyword>
  <keyword>Venous thromboembolism</keyword>
  <keyword>DVT</keyword>
  <keyword>pulmonary embolism</keyword>
  <keyword>VTE</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Male or female participants &gt;=35 years of age with scheduled for primary elective unilateral total knee arthroplasty were recruited at 82 centers from 13 countries. The study was conducted between 28 September 2005 and 27 September 2006.</recruitment_details>
      <pre_assignment_details>A total of 958 participants were randomized into the study. Two participants each from the treatment arm Odiparcil 250 milligram (mg), and Odiparcil 375 mg did not receive the study medication. Therefore, the intent to treat (ITT) population was comprised of 954 participants.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Odiparcil MR 250 mg Tablet</title>
          <description>Eligible participants received Odiparcil modified release (MR) 250 mg tablet at every 12 hours interval (Q12h)for the duration of 10 ± 2 days of double-blind treatment period.</description>
        </group>
        <group group_id="P2">
          <title>Odiparcil MR 375 mg Tablet</title>
          <description>Eligible participants received Odiparcil MR 375 mg tablet at Q12h for the duration of 10 ± 2 days of double-blind treatment period.</description>
        </group>
        <group group_id="P3">
          <title>Odiparcil MR 500 mg Tablet</title>
          <description>Eligible participants received Odiparcil MR 500 mg tablet at Q12h for the duration of 10 ± 2 days of double-blind treatment period.</description>
        </group>
        <group group_id="P4">
          <title>Warfarin INR 2.0 to 3.0</title>
          <description>Eligible participants received overencapsulated warfarin 1 mg and 5 mg as guided by investigator to adjust warfarin to a target International Normalized Ratio (INR) of 2.0 to 3.0 according to the investigators practice or participant status for the duration of 10 ± 2 days of double-blind treatment period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="237"/>
                <participants group_id="P2" count="245"/>
                <participants group_id="P3" count="239"/>
                <participants group_id="P4" count="237"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="214"/>
                <participants group_id="P2" count="226"/>
                <participants group_id="P3" count="215"/>
                <participants group_id="P4" count="216"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="24"/>
                <participants group_id="P4" count="21"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not meet treatment eligibility criteria</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Events</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrwal by participant</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Liver function test abnormality</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor withdrew the participant</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Mediciation Error</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Rehab Refused to allow participantion</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Headache</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Received prohibited medication</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Confirmed venous thromboembolism (VTE)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative reason</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Vomit</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Failed to follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Odiparcil MR 250 mg Tablet</title>
          <description>Eligible participants received Odiparcil MR 250 mg tablet, Q12h for the duration of 10 ± 2 days of double-blind treatment period.</description>
        </group>
        <group group_id="B2">
          <title>Odiparcil MR 375 mg Tablet</title>
          <description>Eligible participants received Odiparcil MR 375 mg tablet, Q12h for the duration of 10 ± 2 days of double-blind treatment period.</description>
        </group>
        <group group_id="B3">
          <title>Odiparcil MR 500 mg Tablet</title>
          <description>Eligible participants received Odiparcil MR 500 mg tablet, Q12h for the duration of 10 ± 2 days of double-blind treatment period.</description>
        </group>
        <group group_id="B4">
          <title>Warfarin INR 2.0 to 3.0</title>
          <description>Eligible participants received overencapsulated warfarin 1 mg and 5 mg as guided by investigator to adjust warfarin to a target INR of 2.0 to 3.0 according to the investigators practice or participant status for the duration of 10 ± 2 days of double-blind treatment period.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="235"/>
            <count group_id="B2" value="243"/>
            <count group_id="B3" value="239"/>
            <count group_id="B4" value="237"/>
            <count group_id="B5" value="954"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.1" spread="9.53"/>
                    <measurement group_id="B2" value="65.3" spread="8.93"/>
                    <measurement group_id="B3" value="64.5" spread="8.68"/>
                    <measurement group_id="B4" value="66.1" spread="9.30"/>
                    <measurement group_id="B5" value="65.5" spread="9.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="150"/>
                    <measurement group_id="B2" value="156"/>
                    <measurement group_id="B3" value="155"/>
                    <measurement group_id="B4" value="150"/>
                    <measurement group_id="B5" value="611"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="84"/>
                    <measurement group_id="B4" value="87"/>
                    <measurement group_id="B5" value="343"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>African American/African Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian - Central/South Asian Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian - East Asian Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian - South East Asian Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White - Arabic/North African Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White - White/Caucasian/European Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="212"/>
                    <measurement group_id="B2" value="224"/>
                    <measurement group_id="B3" value="210"/>
                    <measurement group_id="B4" value="220"/>
                    <measurement group_id="B5" value="866"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mixed Race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Total VTE Event Over 10 ± 2 Days of Treatment</title>
        <description>Participants were assessed for VTE at all study visits and at the end of study (Day 10±2) or at early withdrawal. Any participant who remained asymptomatic for VTE at the end of the study did not receive a mandatory bilateral venogram following at least 8 days on study medication. Participants who were withdrawn early and had been objectively confirmed to have a VTE event by a method other than venography were not required to undergo venography. A participant was included in the Independent Central Adjudication Committee (ICAC)-adjudicated incidence of total VTE if he/ she experienced any of adjudicated asymptomatic deep vein thrombosis (DVT) at early withdrawal or after 8-12 days of study treatment and no later than 1 day after end of study treatment, adjudicated symptomatic DVT or pulmonary embolism (PE) at any time during study treatment or death adjudicated to be related to VTE during study treatment.</description>
        <time_frame>Up to Visit 7 (10 ± 2 days of treatment)</time_frame>
        <population>ITT population comprised of all participants who were randomized and received at least one dose of study treatment. Total number of participants with objectively confirmed symptomatic VTE, venographically detected VTE at early withdrawal or an evaluable venogram at study completion were used for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Odiparcil MR 250 mg Tablet</title>
            <description>Eligible participants received Odiparcil MR 250 mg tablet, Q12h for the duration of 10 ± 2 days of double-blind treatment period.</description>
          </group>
          <group group_id="O2">
            <title>Odiparcil MR 375 mg Tablet</title>
            <description>Eligible participants received Odiparcil MR 375 mg tablet, Q12h for the duration of 10 ± 2 days of double-blind treatment period.</description>
          </group>
          <group group_id="O3">
            <title>Odiparcil MR 500 mg Tablet</title>
            <description>Eligible participants received Odiparcil MR 500 mg tablet, Q12h for the duration of 10 ± 2 days of double-blind treatment period.</description>
          </group>
          <group group_id="O4">
            <title>Warfarin INR 2.0 to 3.0</title>
            <description>Eligible participants received overencapsulated warfarin 1 mg and 5 mg as guided by investigator to adjust warfarin to a target INR of 2.0 to 3.0 according to the investigators practice or participant status for the duration of 10 ± 2 days of double-blind treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Total VTE Event Over 10 ± 2 Days of Treatment</title>
          <description>Participants were assessed for VTE at all study visits and at the end of study (Day 10±2) or at early withdrawal. Any participant who remained asymptomatic for VTE at the end of the study did not receive a mandatory bilateral venogram following at least 8 days on study medication. Participants who were withdrawn early and had been objectively confirmed to have a VTE event by a method other than venography were not required to undergo venography. A participant was included in the Independent Central Adjudication Committee (ICAC)-adjudicated incidence of total VTE if he/ she experienced any of adjudicated asymptomatic deep vein thrombosis (DVT) at early withdrawal or after 8-12 days of study treatment and no later than 1 day after end of study treatment, adjudicated symptomatic DVT or pulmonary embolism (PE) at any time during study treatment or death adjudicated to be related to VTE during study treatment.</description>
          <population>ITT population comprised of all participants who were randomized and received at least one dose of study treatment. Total number of participants with objectively confirmed symptomatic VTE, venographically detected VTE at early withdrawal or an evaluable venogram at study completion were used for analysis.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="169"/>
                <count group_id="O3" value="160"/>
                <count group_id="O4" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.1" lower_limit="37.4" upper_limit="53.1"/>
                    <measurement group_id="O2" value="44.4" lower_limit="36.8" upper_limit="52.2"/>
                    <measurement group_id="O3" value="41.3" lower_limit="33.5" upper_limit="49.3"/>
                    <measurement group_id="O4" value="31.2" lower_limit="24.1" upper_limit="39.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.012</p_value>
            <method>Fisher Exact</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.45</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.1</ci_lower_limit>
            <ci_upper_limit>1.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.017</p_value>
            <method>Fisher Exact</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.42</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.1</ci_lower_limit>
            <ci_upper_limit>1.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.080</p_value>
            <method>Fisher Exact</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.0</ci_lower_limit>
            <ci_upper_limit>1.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Proximal DVT Over 10 ± 2 Days of Treatment</title>
        <description>Proximal DVT is defined as DVT in or above the popliteal vein. A participant was considered to have had an asymptomatic evaluable venogram if the ICAC answer to the DVT question was ‘Yes’ or ‘No’, and to have had an adjudicated asymptomatic DVT if the answer was ‘Yes’. A participant who reported symptoms of DVT was considered to had an adjudicated objectively confirmed symptomatic DVT if the ICAC answer to the question ‘Was a symptomatic DVT identified?’ was ‘Yes’ and the event happened no more than 12 days after start of study treatment (unless exemption for extended treatment was granted by the medical monitor) and no more than 1 day after end of study treatment. In both asymptomatic and symptomatic DVT, the participant was considered to had a proximal DVT if either of the ICAC answers to the questions ‘Left proximal’ and ‘Right proximal’ was ‘DVT’. Percentage of participants with proximal DVT over 10 ± 2 days of treatment were reported.</description>
        <time_frame>Up to 12 days</time_frame>
        <population>ITT population. The participants from ITT population who were with objectively confirmed symptomatic VTE, venographically detected VTE at early withdrawal or an evaluable venogram at completion of study treatment were used for the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Odiparcil MR 250 mg Tablet</title>
            <description>Eligible participants received Odiparcil MR 250 mg tablet, Q12h for the duration of 10 ± 2 days of double-blind treatment period.</description>
          </group>
          <group group_id="O2">
            <title>Odiparcil MR 375 mg Tablet</title>
            <description>Eligible participants received Odiparcil MR 375 mg tablet, Q12h for the duration of 10 ± 2 days of double-blind treatment period.</description>
          </group>
          <group group_id="O3">
            <title>Odiparcil MR 500 mg Tablet</title>
            <description>Eligible participants received Odiparcil MR 500 mg tablet, Q12h for the duration of 10 ± 2 days of double-blind treatment period.</description>
          </group>
          <group group_id="O4">
            <title>Warfarin INR 2.0 to 3.0</title>
            <description>Eligible participants received overencapsulated warfarin 1 mg and 5 mg as guided by investigator to adjust warfarin to a target INR of 2.0 to 3.0 according to the investigators practice or participant status for the duration of 10 ± 2 days of double-blind treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Proximal DVT Over 10 ± 2 Days of Treatment</title>
          <description>Proximal DVT is defined as DVT in or above the popliteal vein. A participant was considered to have had an asymptomatic evaluable venogram if the ICAC answer to the DVT question was ‘Yes’ or ‘No’, and to have had an adjudicated asymptomatic DVT if the answer was ‘Yes’. A participant who reported symptoms of DVT was considered to had an adjudicated objectively confirmed symptomatic DVT if the ICAC answer to the question ‘Was a symptomatic DVT identified?’ was ‘Yes’ and the event happened no more than 12 days after start of study treatment (unless exemption for extended treatment was granted by the medical monitor) and no more than 1 day after end of study treatment. In both asymptomatic and symptomatic DVT, the participant was considered to had a proximal DVT if either of the ICAC answers to the questions ‘Left proximal’ and ‘Right proximal’ was ‘DVT’. Percentage of participants with proximal DVT over 10 ± 2 days of treatment were reported.</description>
          <population>ITT population. The participants from ITT population who were with objectively confirmed symptomatic VTE, venographically detected VTE at early withdrawal or an evaluable venogram at completion of study treatment were used for the analysis.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="169"/>
                <count group_id="O3" value="160"/>
                <count group_id="O4" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Asymptomatic, Proximal DVT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" lower_limit="0.4" upper_limit="5.3"/>
                    <measurement group_id="O2" value="1.8" lower_limit="0.4" upper_limit="5.1"/>
                    <measurement group_id="O3" value="4.4" lower_limit="1.8" upper_limit="8.8"/>
                    <measurement group_id="O4" value="0.6" lower_limit="0.0" upper_limit="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Symptomatic, Proximal DVT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="2.2"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.2"/>
                    <measurement group_id="O3" value="0.6" lower_limit="0.0" upper_limit="3.4"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total, Proximal DVT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" lower_limit="0.4" upper_limit="5.3"/>
                    <measurement group_id="O2" value="1.8" lower_limit="0.4" upper_limit="5.1"/>
                    <measurement group_id="O3" value="5.0" lower_limit="2.2" upper_limit="9.6"/>
                    <measurement group_id="O4" value="0.6" lower_limit="0.0" upper_limit="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Distal DVT Over 10 ± 2 Days of Treatment</title>
        <description>A participant was considered to have had an asymptomatic evaluable venogram if the ICAC answer to the DVT question was ‘Yes’ or ‘No’, and to have had an adjudicated asymptomatic DVT if the answer was ‘Yes’. A participant who reported symptoms of DVT was considered to had an adjudicated objectively confirmed symptomatic DVT if the ICAC answer to the question ‘Was a symptomatic DVT identified?’ was ‘Yes’ and the event happened no more than 12 days after start of study treatment (unless exemption for extended treatment was granted by the medical monitor) and no more than 1 day after end of study treatment. In both asymptomatic and symptomatic DVT, the participant was considered to had a distal DVT if either of the investigator’s answers to the questions ‘Left distal’ and ‘Right distal’ is ‘DVT’.</description>
        <time_frame>Up to 12 days</time_frame>
        <population>ITT population. The participants from ITT population who were with objectively confirmed symptomatic VTE, venographically detected VTE at early withdrawal or an evaluable venogram at completion of study treatment were used for the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Odiparcil MR 250 mg Tablet</title>
            <description>Eligible participants received Odiparcil MR 250 mg tablet, Q12h for the duration of 10 ± 2 days of double-blind treatment period.</description>
          </group>
          <group group_id="O2">
            <title>Odiparcil MR 375 mg Tablet</title>
            <description>Eligible participants received Odiparcil MR 375 mg tablet, Q12h for the duration of 10 ± 2 days of double-blind treatment period.</description>
          </group>
          <group group_id="O3">
            <title>Odiparcil MR 500 mg Tablet</title>
            <description>Eligible participants received Odiparcil MR 500 mg tablet, Q12h for the duration of 10 ± 2 days of double-blind treatment period.</description>
          </group>
          <group group_id="O4">
            <title>Warfarin INR 2.0 to 3.0</title>
            <description>Eligible participants received overencapsulated warfarin 1 mg and 5 mg as guided by investigator to adjust warfarin to a target INR of 2.0 to 3.0 according to the investigators practice or participant status for the duration of 10 ± 2 days of double-blind treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Distal DVT Over 10 ± 2 Days of Treatment</title>
          <description>A participant was considered to have had an asymptomatic evaluable venogram if the ICAC answer to the DVT question was ‘Yes’ or ‘No’, and to have had an adjudicated asymptomatic DVT if the answer was ‘Yes’. A participant who reported symptoms of DVT was considered to had an adjudicated objectively confirmed symptomatic DVT if the ICAC answer to the question ‘Was a symptomatic DVT identified?’ was ‘Yes’ and the event happened no more than 12 days after start of study treatment (unless exemption for extended treatment was granted by the medical monitor) and no more than 1 day after end of study treatment. In both asymptomatic and symptomatic DVT, the participant was considered to had a distal DVT if either of the investigator’s answers to the questions ‘Left distal’ and ‘Right distal’ is ‘DVT’.</description>
          <population>ITT population. The participants from ITT population who were with objectively confirmed symptomatic VTE, venographically detected VTE at early withdrawal or an evaluable venogram at completion of study treatment were used for the analysis.</population>
          <units>Percentage of paticipants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="169"/>
                <count group_id="O3" value="160"/>
                <count group_id="O4" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Asymptomatic, Distal DVT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.1" lower_limit="34.4" upper_limit="50.0"/>
                    <measurement group_id="O2" value="43.8" lower_limit="36.2" upper_limit="51.6"/>
                    <measurement group_id="O3" value="38.8" lower_limit="31.2" upper_limit="46.8"/>
                    <measurement group_id="O4" value="30.6" lower_limit="23.5" upper_limit="38.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Symptomatic, Distal DVT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" lower_limit="0.4" upper_limit="5.3"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.2"/>
                    <measurement group_id="O3" value="0.6" lower_limit="0.0" upper_limit="3.4"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total, Distal DVT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.9" lower_limit="36.2" upper_limit="51.9"/>
                    <measurement group_id="O2" value="43.8" lower_limit="36.2" upper_limit="51.6"/>
                    <measurement group_id="O3" value="39.4" lower_limit="31.8" upper_limit="47.4"/>
                    <measurement group_id="O4" value="30.6" lower_limit="23.5" upper_limit="38.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With PE Over 10 ± 2 Days of Treatment</title>
        <description>Participant who reported symptoms of PE were considered to have had an adjudicated objectively confirmed symptomatic PE if the ICAC answer to the question ‘Was a PE identified?’ was ‘Yes’. E was characterized as fatal PE non-fatal PE and total PE events. Data has been presented for fatal PE non-fatal PE and total PE events over 12 days.</description>
        <time_frame>Up to 12 days</time_frame>
        <population>ITT population. The participants from ITT population who were with objectively confirmed symptomatic VTE, venographically detected VTE at early withdrawal or an evaluable venogram at completion of study treatment were used for the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Odiparcil MR 250 mg Tablet</title>
            <description>Eligible participants received Odiparcil MR 250 mg tablet, Q12h for the duration of 10 ± 2 days of double-blind treatment period.</description>
          </group>
          <group group_id="O2">
            <title>Odiparcil MR 375 mg Tablet</title>
            <description>Eligible participants received Odiparcil MR 375 mg tablet, Q12h for the duration of 10 ± 2 days of double-blind treatment period.</description>
          </group>
          <group group_id="O3">
            <title>Odiparcil MR 500 mg Tablet</title>
            <description>Eligible participants received Odiparcil MR 500 mg tablet, Q12h for the duration of 10 ± 2 days of double-blind treatment period.</description>
          </group>
          <group group_id="O4">
            <title>Warfarin INR 2.0 to 3.0</title>
            <description>Eligible participants received overencapsulated warfarin 1 mg and 5 mg as guided by investigator to adjust warfarin to a target INR of 2.0 to 3.0 according to the investigators practice or participant status for the duration of 10 ± 2 days of double-blind treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With PE Over 10 ± 2 Days of Treatment</title>
          <description>Participant who reported symptoms of PE were considered to have had an adjudicated objectively confirmed symptomatic PE if the ICAC answer to the question ‘Was a PE identified?’ was ‘Yes’. E was characterized as fatal PE non-fatal PE and total PE events. Data has been presented for fatal PE non-fatal PE and total PE events over 12 days.</description>
          <population>ITT population. The participants from ITT population who were with objectively confirmed symptomatic VTE, venographically detected VTE at early withdrawal or an evaluable venogram at completion of study treatment were used for the analysis.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="169"/>
                <count group_id="O3" value="160"/>
                <count group_id="O4" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fatal PE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="2.2"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.2"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.3"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-fatal PE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" lower_limit="0.1" upper_limit="4.3"/>
                    <measurement group_id="O2" value="0.6" lower_limit="0.0" upper_limit="3.3"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.3"/>
                    <measurement group_id="O4" value="0.6" lower_limit="0.0" upper_limit="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total PE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" lower_limit="0.1" upper_limit="4.3"/>
                    <measurement group_id="O2" value="0.6" lower_limit="0.0" upper_limit="3.3"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.3"/>
                    <measurement group_id="O4" value="0.6" lower_limit="0.0" upper_limit="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Death Due to VTE Over 10 ± 2 Days of Treatment</title>
        <description>A participant was considered dead from an adjudicated VTE-related cause if the death classification was recorded as ‘Fatal PE’. A participant was considered to have died from an investigator-assessed VTE-related cause if the investigator’s death classification was recorded as ‘Fatal PE’. Number of death due to VTE over 10 ± 2 days of treatment were reported.</description>
        <time_frame>Up to 12 days</time_frame>
        <population>ITT population. The participants from ITT population who were with objectively confirmed symptomatic VTE, venographically detected VTE at early withdrawal or an evaluable venogram at completion of study treatment were used for the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Odiparcil MR 250 mg Tablet</title>
            <description>Eligible participants received Odiparcil MR 250 mg tablet, Q12h for the duration of 10 ± 2 days of double-blind treatment period.</description>
          </group>
          <group group_id="O2">
            <title>Odiparcil MR 375 mg Tablet</title>
            <description>Eligible participants received Odiparcil MR 375 mg tablet, Q12h for the duration of 10 ± 2 days of double-blind treatment period.</description>
          </group>
          <group group_id="O3">
            <title>Odiparcil MR 500 mg Tablet</title>
            <description>Eligible participants received Odiparcil MR 500 mg tablet, Q12h for the duration of 10 ± 2 days of double-blind treatment period.</description>
          </group>
          <group group_id="O4">
            <title>Warfarin INR 2.0 to 3.0</title>
            <description>Eligible participants received overencapsulated warfarin 1 mg and 5 mg as guided by investigator to adjust warfarin to a target INR of 2.0 to 3.0 according to the investigators practice or participant status for the duration of 10 ± 2 days of double-blind treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Death Due to VTE Over 10 ± 2 Days of Treatment</title>
          <description>A participant was considered dead from an adjudicated VTE-related cause if the death classification was recorded as ‘Fatal PE’. A participant was considered to have died from an investigator-assessed VTE-related cause if the investigator’s death classification was recorded as ‘Fatal PE’. Number of death due to VTE over 10 ± 2 days of treatment were reported.</description>
          <population>ITT population. The participants from ITT population who were with objectively confirmed symptomatic VTE, venographically detected VTE at early withdrawal or an evaluable venogram at completion of study treatment were used for the analysis.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="169"/>
                <count group_id="O3" value="160"/>
                <count group_id="O4" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Total Asymptomatic VTE Over 10 ± 2 Days of Treatment</title>
        <description>A participant was included in the Independent Central Adjudication Committee (ICAC)-adjudicated incidence of total VTE if experienced any of adjudicated asymptomatic deep vein thrombosis (DVT) at early withdrawal or after 8-12 days of study treatment and no later than 1 day after end of study treatment, adjudicated symptomatic DVT or PE at any time during study treatment or death adjudicated to be related to VTE during study treatment. A participant was considered to have had an asymptomatic evaluable venogram if the ICAC answer to the DVT question was ‘Yes’ or ‘No’, and to have had an adjudicated asymptomatic DVT if the answer was ‘Yes’. The participant was considered to had a proximal DVT if either of the investigator’s answers to the questions ‘Left distal’ and ‘Right distal’ is ‘DVT’. The participant was considered to had a distal DVT if either of the investigator’s answers to the questions ‘Left distal’ and ‘Right distal’ is ‘DVT’.</description>
        <time_frame>Up to 12 days</time_frame>
        <population>ITT population. The participants from ITT population who were with objectively confirmed symptomatic VTE, venographically detected VTE at early withdrawal or an evaluable venogram at completion of study treatment were used for the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Odiparcil MR 250 mg Tablet</title>
            <description>Eligible participants received Odiparcil MR 250 mg tablet, Q12h for the duration of 10 ± 2 days of double-blind treatment period.</description>
          </group>
          <group group_id="O2">
            <title>Odiparcil MR 375 mg Tablet</title>
            <description>Eligible participants received Odiparcil MR 375 mg tablet, Q12h for the duration of 10 ± 2 days of double-blind treatment period.</description>
          </group>
          <group group_id="O3">
            <title>Odiparcil MR 500 mg Tablet</title>
            <description>Eligible participants received Odiparcil MR 500 mg tablet, Q12h for the duration of 10 ± 2 days of double-blind treatment period.</description>
          </group>
          <group group_id="O4">
            <title>Warfarin INR 2.0 to 3.0</title>
            <description>Eligible participants received overencapsulated warfarin 1 mg and 5 mg as guided by investigator to adjust warfarin to a target INR of 2.0 to 3.0 according to the investigators practice or participant status for the duration of 10 ± 2 days of double-blind treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Total Asymptomatic VTE Over 10 ± 2 Days of Treatment</title>
          <description>A participant was included in the Independent Central Adjudication Committee (ICAC)-adjudicated incidence of total VTE if experienced any of adjudicated asymptomatic deep vein thrombosis (DVT) at early withdrawal or after 8-12 days of study treatment and no later than 1 day after end of study treatment, adjudicated symptomatic DVT or PE at any time during study treatment or death adjudicated to be related to VTE during study treatment. A participant was considered to have had an asymptomatic evaluable venogram if the ICAC answer to the DVT question was ‘Yes’ or ‘No’, and to have had an adjudicated asymptomatic DVT if the answer was ‘Yes’. The participant was considered to had a proximal DVT if either of the investigator’s answers to the questions ‘Left distal’ and ‘Right distal’ is ‘DVT’. The participant was considered to had a distal DVT if either of the investigator’s answers to the questions ‘Left distal’ and ‘Right distal’ is ‘DVT’.</description>
          <population>ITT population. The participants from ITT population who were with objectively confirmed symptomatic VTE, venographically detected VTE at early withdrawal or an evaluable venogram at completion of study treatment were used for the analysis.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="169"/>
                <count group_id="O3" value="160"/>
                <count group_id="O4" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.1" lower_limit="34.4" upper_limit="50.0"/>
                    <measurement group_id="O2" value="43.8" lower_limit="36.2" upper_limit="51.6"/>
                    <measurement group_id="O3" value="40.0" lower_limit="32.3" upper_limit="48.0"/>
                    <measurement group_id="O4" value="30.6" lower_limit="23.5" upper_limit="38.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Total Symptomatic VTE Over 10 ± 2 Days of Treatment</title>
        <description>A participant who reported symptoms of DVT was considered to had an adjudicated objectively confirmed symptomatic DVT if the ICAC answer to the question ‘Was a symptomatic DVT identified?’ was ‘Yes’ and the event happened no more than 12 days after start of study treatment (unless exemption for extended treatment was granted by the medical monitor) and no more than 1 day after end of study treatment. The participant was considered to had a proximal DVT if either of the investigator’s answers to the questions ‘Left distal’ and ‘Right distal’ was ‘DVT’. The participant was considered to had a distal DVT if either of the investigator’s answers to the questions ‘Left distal’ and ‘Right distal’ was ‘DVT’. Percentage of participants with total symptomatic (distal and proximal) VTE over 10 ± 2 days of treatment were reported.</description>
        <time_frame>Up to 12 days</time_frame>
        <population>ITT population. The participants from ITT population who were with objectively confirmed symptomatic VTE, venographically detected VTE at early withdrawal or an evaluable venogram at completion of study treatment were used for the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Odiparcil MR 250 mg Tablet</title>
            <description>Eligible participants received Odiparcil MR 250 mg tablet, Q12h for the duration of 10 ± 2 days of double-blind treatment period.</description>
          </group>
          <group group_id="O2">
            <title>Odiparcil MR 375 mg Tablet</title>
            <description>Eligible participants received Odiparcil MR 375 mg tablet, Q12h for the duration of 10 ± 2 days of double-blind treatment period.</description>
          </group>
          <group group_id="O3">
            <title>Odiparcil MR 500 mg Tablet</title>
            <description>Eligible participants received Odiparcil MR 500 mg tablet, Q12h for the duration of 10 ± 2 days of double-blind treatment period.</description>
          </group>
          <group group_id="O4">
            <title>Warfarin INR 2.0 to 3.0</title>
            <description>Eligible participants received overencapsulated warfarin 1 mg and 5 mg as guided by investigator to adjust warfarin to a target INR of 2.0 to 3.0 according to the investigators practice or participant status for the duration of 10 ± 2 days of double-blind treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Total Symptomatic VTE Over 10 ± 2 Days of Treatment</title>
          <description>A participant who reported symptoms of DVT was considered to had an adjudicated objectively confirmed symptomatic DVT if the ICAC answer to the question ‘Was a symptomatic DVT identified?’ was ‘Yes’ and the event happened no more than 12 days after start of study treatment (unless exemption for extended treatment was granted by the medical monitor) and no more than 1 day after end of study treatment. The participant was considered to had a proximal DVT if either of the investigator’s answers to the questions ‘Left distal’ and ‘Right distal’ was ‘DVT’. The participant was considered to had a distal DVT if either of the investigator’s answers to the questions ‘Left distal’ and ‘Right distal’ was ‘DVT’. Percentage of participants with total symptomatic (distal and proximal) VTE over 10 ± 2 days of treatment were reported.</description>
          <population>ITT population. The participants from ITT population who were with objectively confirmed symptomatic VTE, venographically detected VTE at early withdrawal or an evaluable venogram at completion of study treatment were used for the analysis.</population>
          <units>Perentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="169"/>
                <count group_id="O3" value="160"/>
                <count group_id="O4" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" lower_limit="0.4" upper_limit="5.3"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.2"/>
                    <measurement group_id="O3" value="1.3" lower_limit="0.2" upper_limit="4.4"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentration of Trough Anti-IIa Activity Over the Duration of Treatment and Follow-up</title>
        <description>In all participants, additional 3 milliliter of blood was collected at the time of other blood sampling as follow: Baseline, Day 3 (predose, 2, 4, 8, 10, and 12 hours post dose), Day 5 (predose), and Day 10 (predose) or early withdrawal from study medication for the assessment of anti-factor IIa activity. Samples were collected in 3.8% sodium citrate tubes and immediately chilled in ice. Plasma were centrifuged and frozen at approximately -20ºC until time of shipment to the regional central laboratory. Concentration of Trough Anti-IIa Activity over the duration of treatment and follow-up were reported.</description>
        <time_frame>Up to 68 days</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Odiparcil MR 250 mg Tablet</title>
            <description>Eligible participants received Odiparcil MR 250 mg tablet, Q12h for the duration of 10 ± 2 days of double-blind treatment period.</description>
          </group>
          <group group_id="O2">
            <title>Odiparcil MR 375 mg Tablet</title>
            <description>Eligible participants received Odiparcil MR 375 mg tablet, Q12h for the duration of 10 ± 2 days of double-blind treatment period.</description>
          </group>
          <group group_id="O3">
            <title>Odiparcil MR 500 mg Tablet</title>
            <description>Eligible participants received Odiparcil MR 500 mg tablet, Q12h for the duration of 10 ± 2 days of double-blind treatment period.</description>
          </group>
          <group group_id="O4">
            <title>Warfarin INR 2.0 to 3.0</title>
            <description>Eligible participants received overencapsulated warfarin 1 mg and 5 mg as guided by investigator to adjust warfarin to a target INR of 2.0 to 3.0 according to the investigators practice or participant status for the duration of 10 ± 2 days of double-blind treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration of Trough Anti-IIa Activity Over the Duration of Treatment and Follow-up</title>
          <description>In all participants, additional 3 milliliter of blood was collected at the time of other blood sampling as follow: Baseline, Day 3 (predose, 2, 4, 8, 10, and 12 hours post dose), Day 5 (predose), and Day 10 (predose) or early withdrawal from study medication for the assessment of anti-factor IIa activity. Samples were collected in 3.8% sodium citrate tubes and immediately chilled in ice. Plasma were centrifuged and frozen at approximately -20ºC until time of shipment to the regional central laboratory. Concentration of Trough Anti-IIa Activity over the duration of treatment and follow-up were reported.</description>
          <population>ITT population.</population>
          <units>Microgram per millilitre (mcg/ml)</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="235"/>
                <count group_id="O2" value="243"/>
                <count group_id="O3" value="239"/>
                <count group_id="O4" value="237"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 3, n= 224, 221, 223, 220</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.44" spread="1.944"/>
                    <measurement group_id="O2" value="3.15" spread="2.667"/>
                    <measurement group_id="O3" value="3.75" spread="2.702"/>
                    <measurement group_id="O4" value="0.26" spread="0.041"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5, n= 201, 207, 215, 203</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.73" spread="1.456"/>
                    <measurement group_id="O2" value="2.43" spread="1.924"/>
                    <measurement group_id="O3" value="3.07" spread="2.440"/>
                    <measurement group_id="O4" value="0.27" spread="0.099"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10, n= 179, 197, 199, 181</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.45" spread="1.298"/>
                    <measurement group_id="O2" value="2.23" spread="1.830"/>
                    <measurement group_id="O3" value="2.45" spread="2.042"/>
                    <measurement group_id="O4" value="0.25" spread="0.020"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Early Withdraw On-therapy, n= 13, 8, 10, 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.73" spread="1.286"/>
                    <measurement group_id="O2" value="3.73" spread="2.684"/>
                    <measurement group_id="O3" value="2.49" spread="3.072"/>
                    <measurement group_id="O4" value="0.29" spread="0.159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>14 Day FU, n= 16, 11, 5, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.95" spread="1.086"/>
                    <measurement group_id="O2" value="1.16" spread="1.431"/>
                    <measurement group_id="O3" value="1.02" spread="1.652"/>
                    <measurement group_id="O4" value="0.30" spread="0.109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Early Withdraw 14 Day FU, n= 13, 15, 6, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.46" spread="0.376"/>
                    <measurement group_id="O2" value="0.74" spread="0.767"/>
                    <measurement group_id="O3" value="0.60" spread="0.666"/>
                    <measurement group_id="O4" value="0.25" spread="0.008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>28 Day FU, n= 0, 1, 0, 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Participants were not analyzed at this time point.</measurement>
                    <measurement group_id="O2" value="0.25">Standard deviation was not derived as only one participant was available at the time of analysis analyzed.</measurement>
                    <measurement group_id="O3" value="NA">Participants were not analyzed at this time point.</measurement>
                    <measurement group_id="O4" value="0.25">Standard deviation was not derived as only one participant was available at the time of analysis analyzed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Early Withdraw 28 Day FU, n=0, 1, 0, 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Participants were not analyzed at this time point.</measurement>
                    <measurement group_id="O2" value="0.25">Standard deviation was not derived as only one participant was available at the time of analysis analyzed.</measurement>
                    <measurement group_id="O3" value="NA">Participants were not analyzed at this time point.</measurement>
                    <measurement group_id="O4" value="0.25">Standard deviation was not derived as only one participant was available at the time of analysis analyzed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Major Bleeds Over 10 ± 2 Days of Treatment</title>
        <description>A participant was included in the ICAC-adjudicated incidence of major bleeding if participant experienced an adjudicated major bleed up to 12 days after the start of study treatment and no later than 1 day after end of study treatment. Major bleed was defined as clinically overt bleeding, 1) Clinical overt bleeding: clinically apparent bleeding or signs and/or symptoms suggestive of bleeding with confirmatory imaging studies (e.g., ultrasound, computed tomography) 2. Critical Site Involvement: Intracranial, retroperitoneal, intra-ocular, intraspinal, pericardial. 3. Decrease in Hgb &gt; 2 g/dL from baseline, 4. Transfusion of &gt; 2 units of packed RBCs, 5. Medical or Surgical Intervention for the Reported Bleed, 6. Fatal Bleed. If the event satisfied one of the above criteria.</description>
        <time_frame>Up to 12 days</time_frame>
        <population>ITT Population. The participants from ITT population who completed study treatment (Day-10 visit) or reported a major bleed by the time of early withdrawal were used for the analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Odiparcil MR 250 mg Tablet</title>
            <description>Eligible participants received Odiparcil MR 250 mg tablet, Q12h for the duration of 10 ± 2 days of double-blind treatment period.</description>
          </group>
          <group group_id="O2">
            <title>Odiparcil MR 375 mg Tablet</title>
            <description>Eligible participants received Odiparcil MR 375 mg tablet, Q12h for the duration of 10 ± 2 days of double-blind treatment period.</description>
          </group>
          <group group_id="O3">
            <title>Odiparcil MR 500 mg Tablet</title>
            <description>Eligible participants received Odiparcil MR 500 mg tablet, Q12h for the duration of 10 ± 2 days of double-blind treatment period.</description>
          </group>
          <group group_id="O4">
            <title>Warfarin INR 2.0 to 3.0</title>
            <description>Eligible participants received overencapsulated warfarin 1 mg and 5 mg as guided by investigator to adjust warfarin to a target INR of 2.0 to 3.0 according to the investigators practice or participant status for the duration of 10 ± 2 days of double-blind treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Major Bleeds Over 10 ± 2 Days of Treatment</title>
          <description>A participant was included in the ICAC-adjudicated incidence of major bleeding if participant experienced an adjudicated major bleed up to 12 days after the start of study treatment and no later than 1 day after end of study treatment. Major bleed was defined as clinically overt bleeding, 1) Clinical overt bleeding: clinically apparent bleeding or signs and/or symptoms suggestive of bleeding with confirmatory imaging studies (e.g., ultrasound, computed tomography) 2. Critical Site Involvement: Intracranial, retroperitoneal, intra-ocular, intraspinal, pericardial. 3. Decrease in Hgb &gt; 2 g/dL from baseline, 4. Transfusion of &gt; 2 units of packed RBCs, 5. Medical or Surgical Intervention for the Reported Bleed, 6. Fatal Bleed. If the event satisfied one of the above criteria.</description>
          <population>ITT Population. The participants from ITT population who completed study treatment (Day-10 visit) or reported a major bleed by the time of early withdrawal were used for the analysis</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="217"/>
                <count group_id="O3" value="222"/>
                <count group_id="O4" value="203"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="1.8"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="1.7"/>
                    <measurement group_id="O3" value="0.9" lower_limit="0.1" upper_limit="3.2"/>
                    <measurement group_id="O4" value="1.0" lower_limit="0.1" upper_limit="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With VTE and/or Major Bleeding Over 10±2 Days of Treatment</title>
        <description>A participant was included in the ICAC-adjudicated incidence of major bleeding if experienced an adjudicated major bleed up to 12 days after the start of study treatment and no later than 1 day after end of study treatment. Percentage of participants with VTE and/or major bleeding over 10±2 days of treatment were reported.</description>
        <time_frame>Up to 12 days</time_frame>
        <population>ITT population. The participants from ITT population who were efficacy evaluable or reported a major bleed or VTE by the time of early withdrawal were used for the analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Odiparcil MR 250 mg Tablet</title>
            <description>Eligible participants received Odiparcil MR 250 mg tablet, Q12h for the duration of 10 ± 2 days of double-blind treatment period.</description>
          </group>
          <group group_id="O2">
            <title>Odiparcil MR 375 mg Tablet</title>
            <description>Eligible participants received Odiparcil MR 375 mg tablet, Q12h for the duration of 10 ± 2 days of double-blind treatment period.</description>
          </group>
          <group group_id="O3">
            <title>Odiparcil MR 500 mg Tablet</title>
            <description>Eligible participants received Odiparcil MR 500 mg tablet, Q12h for the duration of 10 ± 2 days of double-blind treatment period.</description>
          </group>
          <group group_id="O4">
            <title>Warfarin INR 2.0 to 3.0</title>
            <description>Eligible participants received overencapsulated warfarin 1 mg and 5 mg as guided by investigator to adjust warfarin to a target INR of 2.0 to 3.0 according to the investigators practice or participant status for the duration of 10 ± 2 days of double-blind treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With VTE and/or Major Bleeding Over 10±2 Days of Treatment</title>
          <description>A participant was included in the ICAC-adjudicated incidence of major bleeding if experienced an adjudicated major bleed up to 12 days after the start of study treatment and no later than 1 day after end of study treatment. Percentage of participants with VTE and/or major bleeding over 10±2 days of treatment were reported.</description>
          <population>ITT population. The participants from ITT population who were efficacy evaluable or reported a major bleed or VTE by the time of early withdrawal were used for the analysis</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="169"/>
                <count group_id="O3" value="160"/>
                <count group_id="O4" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>VTE and/or major bleed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.1" lower_limit="37.4" upper_limit="53.1"/>
                    <measurement group_id="O2" value="44.4" lower_limit="36.8" upper_limit="52.2"/>
                    <measurement group_id="O3" value="42.5" lower_limit="34.7" upper_limit="50.6"/>
                    <measurement group_id="O4" value="32.5" lower_limit="25.2" upper_limit="40.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VTE and major bleed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="2.2"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.2"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.3"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VTE with no major bleed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.1" lower_limit="37.4" upper_limit="53.1"/>
                    <measurement group_id="O2" value="44.4" lower_limit="36.8" upper_limit="52.2"/>
                    <measurement group_id="O3" value="41.3" lower_limit="33.5" upper_limit="49.3"/>
                    <measurement group_id="O4" value="31.2" lower_limit="24.1" upper_limit="39.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Major bleed with no VTE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="2.2"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="2.2"/>
                    <measurement group_id="O3" value="1.3" lower_limit="0.2" upper_limit="4.4"/>
                    <measurement group_id="O4" value="1.3" lower_limit="0.2" upper_limit="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No VTE and no major bleed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.9" lower_limit="46.9" upper_limit="62.6"/>
                    <measurement group_id="O2" value="55.6" lower_limit="47.8" upper_limit="63.2"/>
                    <measurement group_id="O3" value="58.1" lower_limit="50.1" upper_limit="65.9"/>
                    <measurement group_id="O4" value="68.2" lower_limit="60.3" upper_limit="75.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Total VTE Any Time After Start of Treatment</title>
        <description>Participants were assessed for VTE at all study visits and at the end of the study (Day 10±2) or at early withdrawal. Any participant who remained asymptomatic for VTE at the end of the study were received a mandatory bilateral venogram. Participants who were withdrawn early and had been objectively confirmed to have a VTE event by a method other than venography were not required to undergo venography. A participant was included in the ICAC-adjudicated incidence of total VTE if experienced any of adjudicated asymptomatic DVT at early withdrawal or after 8-12 days of study treatment and no later than 1 day after end of study treatment, adjudicated symptomatic DVT or PE at any time during study treatment or death adjudicated to be related to VTE during study treatment. Percentage of participants with total VTE any time after start of treatment were reported.</description>
        <time_frame>Up to Visit 9 (Day 28 post treatment)</time_frame>
        <population>ITT population. The participants from ITT population who were with objectively confirmed symptomatic VTE, venographically detected VTE at early withdrawal or an evaluable venogram at completion of study treatment were used for the analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Odiparcil MR 250 mg Tablet</title>
            <description>Eligible participants received Odiparcil MR 250 mg tablet, Q12h for the duration of 10 ± 2 days of double-blind treatment period.</description>
          </group>
          <group group_id="O2">
            <title>Odiparcil MR 375 mg Tablet</title>
            <description>Eligible participants received Odiparcil MR 375 mg tablet, Q12h for the duration of 10 ± 2 days of double-blind treatment period.</description>
          </group>
          <group group_id="O3">
            <title>Odiparcil MR 500 mg Tablet</title>
            <description>Eligible participants received Odiparcil MR 500 mg tablet, Q12h for the duration of 10 ± 2 days of double-blind treatment period.</description>
          </group>
          <group group_id="O4">
            <title>Warfarin INR 2.0 to 3.0</title>
            <description>Eligible participants received overencapsulated warfarin 1 mg and 5 mg as guided by investigator to adjust warfarin to a target INR of 2.0 to 3.0 according to the investigators practice or participant status for the duration of 10 ± 2 days of double-blind treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Total VTE Any Time After Start of Treatment</title>
          <description>Participants were assessed for VTE at all study visits and at the end of the study (Day 10±2) or at early withdrawal. Any participant who remained asymptomatic for VTE at the end of the study were received a mandatory bilateral venogram. Participants who were withdrawn early and had been objectively confirmed to have a VTE event by a method other than venography were not required to undergo venography. A participant was included in the ICAC-adjudicated incidence of total VTE if experienced any of adjudicated asymptomatic DVT at early withdrawal or after 8-12 days of study treatment and no later than 1 day after end of study treatment, adjudicated symptomatic DVT or PE at any time during study treatment or death adjudicated to be related to VTE during study treatment. Percentage of participants with total VTE any time after start of treatment were reported.</description>
          <population>ITT population. The participants from ITT population who were with objectively confirmed symptomatic VTE, venographically detected VTE at early withdrawal or an evaluable venogram at completion of study treatment were used for the analysis</population>
          <units>Percenatge of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
                <count group_id="O2" value="179"/>
                <count group_id="O3" value="171"/>
                <count group_id="O4" value="168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.5" lower_limit="38.8" upper_limit="54.3"/>
                    <measurement group_id="O2" value="45.8" lower_limit="38.4" upper_limit="53.4"/>
                    <measurement group_id="O3" value="43.3" lower_limit="35.7" upper_limit="51.1"/>
                    <measurement group_id="O4" value="30.4" lower_limit="23.5" upper_limit="37.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Elevated Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Direct Bilirubin (DB) and Total Bilirubin (TB) by 2 Fold and 3 Fold From Upper Normal Limits (ULN) Any Time On-treatment</title>
        <description>The ranges (low concern value; high concern value) for AST (none; &gt; 3 fold upper normal limit (ULN) ), ALT (none; &gt;3 fold ULN), total bilirubin (none; &gt;= 34.2 micromole per litre [umol/L]), Direct bilirubin (none; &gt;= 34.2 umol/L). Percentage of participants with elevated values by 2 fold and 3 fold from ULN any time on-treatment were reported.</description>
        <time_frame>Up to 12 days</time_frame>
        <population>ITT population. Number of participants were available at the time of analysis were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Odiparcil MR 250 mg Tablet</title>
            <description>Eligible participants received Odiparcil MR 250 mg tablet, Q12h for the duration of 10 ± 2 days of double-blind treatment period.</description>
          </group>
          <group group_id="O2">
            <title>Odiparcil MR 375 mg Tablet</title>
            <description>Eligible participants received Odiparcil MR 375 mg tablet, Q12h for the duration of 10 ± 2 days of double-blind treatment period.</description>
          </group>
          <group group_id="O3">
            <title>Odiparcil MR 500 mg Tablet</title>
            <description>Eligible participants received Odiparcil MR 500 mg tablet, Q12h for the duration of 10 ± 2 days of double-blind treatment period.</description>
          </group>
          <group group_id="O4">
            <title>Warfarin INR 2.0 to 3.0</title>
            <description>Eligible participants received overencapsulated warfarin 1 mg and 5 mg as guided by investigator to adjust warfarin to a target INR of 2.0 to 3.0 according to the investigators practice or participant status for the duration of 10 ± 2 days of double-blind treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Elevated Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Direct Bilirubin (DB) and Total Bilirubin (TB) by 2 Fold and 3 Fold From Upper Normal Limits (ULN) Any Time On-treatment</title>
          <description>The ranges (low concern value; high concern value) for AST (none; &gt; 3 fold upper normal limit (ULN) ), ALT (none; &gt;3 fold ULN), total bilirubin (none; &gt;= 34.2 micromole per litre [umol/L]), Direct bilirubin (none; &gt;= 34.2 umol/L). Percentage of participants with elevated values by 2 fold and 3 fold from ULN any time on-treatment were reported.</description>
          <population>ITT population. Number of participants were available at the time of analysis were included.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="231"/>
                <count group_id="O2" value="235"/>
                <count group_id="O3" value="236"/>
                <count group_id="O4" value="234"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALT, &gt;=2xULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" lower_limit="2.4" upper_limit="8.4"/>
                    <measurement group_id="O2" value="3.8" lower_limit="1.8" upper_limit="7.1"/>
                    <measurement group_id="O3" value="3.8" lower_limit="1.8" upper_limit="7.1"/>
                    <measurement group_id="O4" value="5.6" lower_limit="3.0" upper_limit="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT, &gt;=3xULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" lower_limit="0.1" upper_limit="3.1"/>
                    <measurement group_id="O2" value="2.6" lower_limit="0.9" upper_limit="5.5"/>
                    <measurement group_id="O3" value="0.4" lower_limit="0.0" upper_limit="2.3"/>
                    <measurement group_id="O4" value="2.1" lower_limit="0.7" upper_limit="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, &gt;=2xULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="1.0" upper_limit="5.6"/>
                    <measurement group_id="O2" value="3.4" lower_limit="1.5" upper_limit="6.6"/>
                    <measurement group_id="O3" value="3.8" lower_limit="1.8" upper_limit="7.1"/>
                    <measurement group_id="O4" value="4.7" lower_limit="2.4" upper_limit="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, &gt;=3xULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="1.6"/>
                    <measurement group_id="O2" value="0.9" lower_limit="0.1" upper_limit="3.1"/>
                    <measurement group_id="O3" value="0.4" lower_limit="0.0" upper_limit="2.3"/>
                    <measurement group_id="O4" value="1.7" lower_limit="0.5" upper_limit="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Billirubin, &gt;=2xULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="1.6"/>
                    <measurement group_id="O2" value="0.4" lower_limit="0.0" upper_limit="2.3"/>
                    <measurement group_id="O3" value="0.4" lower_limit="0.0" upper_limit="2.3"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Billirubin, &gt;=3xULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="1.6"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="1.6"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="1.6"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Direct Billirubin, &gt;=2xULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" lower_limit="0.0" upper_limit="2.4"/>
                    <measurement group_id="O2" value="0.4" lower_limit="0.0" upper_limit="2.3"/>
                    <measurement group_id="O3" value="0.4" lower_limit="0.0" upper_limit="2.3"/>
                    <measurement group_id="O4" value="0.9" lower_limit="0.1" upper_limit="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Direct Billirubin, &gt;=3xULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" lower_limit="0.0" upper_limit="2.4"/>
                    <measurement group_id="O2" value="0.4" lower_limit="0.0" upper_limit="2.3"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="1.6"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious adverse events (SAE) and non-serious adverse events (nSAEs) were collected up to follow-up visit (Visit 9, Day 28±2 days after study medication discontinuation). On-treatment nSAEs were reported.</time_frame>
      <desc>ITT population was used for analysis.</desc>
      <group_list>
        <group group_id="E1">
          <title>ODIPARCIL MR 250 mg Tablet</title>
          <description>Eligible participants received Odiparcil MR 250 mg tablet, Q12h for the duration of 10 ± 2 days of double-blind treatment period.</description>
        </group>
        <group group_id="E2">
          <title>ODIPARCIL MR 375 MG TABLET</title>
          <description>Eligible participants received Odiparcil MR 375 mg tablet, Q12h for the duration of 10 ± 2 days of double-blind treatment period.</description>
        </group>
        <group group_id="E3">
          <title>ODIPARCIL MR 500 MG TABLET</title>
          <description>Eligible participants received Odiparcil MR 500 mg tablet, Q12h for the duration of 10 ± 2 days of double-blind treatment period.</description>
        </group>
        <group group_id="E4">
          <title>WARFARIN INR 2.0 TO 3.0</title>
          <description>Eligible participants received overencapsulated warfarin 1 mg and 5 mg as guided by investigator to adjust warfarin to a target INR of 2.0 to 3.0 according to the investigators practice or participant status for the duration of 10 ± 2 days of double-blind treatment period.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="239"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Atrial thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <description>General disorders and administration site conditions</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <description>General disorders and administration site conditions</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Arthritis infective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Bronchitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Postoperative infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Postoperative ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Traumatic haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Bleeding time abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Body temperature increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="124" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="120" subjects_at_risk="243"/>
                <counts group_id="E3" subjects_affected="122" subjects_at_risk="239"/>
                <counts group_id="E4" subjects_affected="104" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="235"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="243"/>
                <counts group_id="E3" events="19" subjects_affected="19" subjects_at_risk="239"/>
                <counts group_id="E4" events="12" subjects_affected="12" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="28" subjects_affected="27" subjects_at_risk="235"/>
                <counts group_id="E2" events="36" subjects_affected="35" subjects_at_risk="243"/>
                <counts group_id="E3" events="41" subjects_affected="40" subjects_at_risk="239"/>
                <counts group_id="E4" events="36" subjects_affected="33" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="30" subjects_affected="29" subjects_at_risk="235"/>
                <counts group_id="E2" events="25" subjects_affected="25" subjects_at_risk="243"/>
                <counts group_id="E3" events="26" subjects_affected="26" subjects_at_risk="239"/>
                <counts group_id="E4" events="31" subjects_affected="29" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="235"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="243"/>
                <counts group_id="E3" events="21" subjects_affected="21" subjects_at_risk="239"/>
                <counts group_id="E4" events="14" subjects_affected="13" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="42" subjects_affected="40" subjects_at_risk="235"/>
                <counts group_id="E2" events="30" subjects_affected="28" subjects_at_risk="243"/>
                <counts group_id="E3" events="29" subjects_affected="29" subjects_at_risk="239"/>
                <counts group_id="E4" events="34" subjects_affected="34" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="30" subjects_affected="27" subjects_at_risk="235"/>
                <counts group_id="E2" events="27" subjects_affected="23" subjects_at_risk="243"/>
                <counts group_id="E3" events="36" subjects_affected="28" subjects_at_risk="239"/>
                <counts group_id="E4" events="35" subjects_affected="25" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Anaemia postoperative</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="235"/>
                <counts group_id="E2" events="21" subjects_affected="21" subjects_at_risk="243"/>
                <counts group_id="E3" events="24" subjects_affected="24" subjects_at_risk="239"/>
                <counts group_id="E4" events="19" subjects_affected="19" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="235"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="243"/>
                <counts group_id="E3" events="10" subjects_affected="8" subjects_at_risk="239"/>
                <counts group_id="E4" events="10" subjects_affected="9" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Body temperature increased</sub_title>
                <counts group_id="E1" events="20" subjects_affected="18" subjects_at_risk="235"/>
                <counts group_id="E2" events="21" subjects_affected="21" subjects_at_risk="243"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="239"/>
                <counts group_id="E4" events="13" subjects_affected="13" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="235"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="243"/>
                <counts group_id="E3" events="14" subjects_affected="13" subjects_at_risk="239"/>
                <counts group_id="E4" events="11" subjects_affected="9" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="235"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="243"/>
                <counts group_id="E3" events="16" subjects_affected="14" subjects_at_risk="239"/>
                <counts group_id="E4" events="14" subjects_affected="11" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="235"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="243"/>
                <counts group_id="E3" events="17" subjects_affected="16" subjects_at_risk="239"/>
                <counts group_id="E4" events="13" subjects_affected="13" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="235"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="243"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="239"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

